Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 18 2024
0mins
Source: newsfilter
- Calliditas Therapeutics Presentation: Calliditas presented additional data analyses from the Phase 3 NeflgArd trial of Nefecon for IgA nephropathy at the ISN World Congress of Nephrology.
- Poster Presentation Analyses: Detailed findings included improved kidney benefits with Nefecon treatment, sustained eGFR improvement, and support in reaching RaDaR treatment targets.
- eGFR Decline Results: Nefecon showed a reduction in UPCR, lower risk of eGFR decline or kidney failure, and delayed time to such events compared to placebo.
- Quality of Life Analysis: SF-36 results showed consistent quality of life between Nefecon and placebo groups over 2 years, supporting the benefit/risk profile of Nefecon.
- Treatment Response Across Populations: Nefecon demonstrated favorable responses in Asian and White patient populations, showing efficacy, tolerability, and reduced microhematuria rates across racial and ethnic groups.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
